Search

Your search keyword '"Hindie, Elif"' showing total 170 results
Start Over Author "Hindie, Elif"
170 results on '"Hindie, Elif"'

1. How to explain the sensitivity of DNA double-strand breaks yield to 125I position?

Author

Ávila, Mario Enrique Alcocer, Hindié, Elif, and Champion, Christophe

Subjects
Physics - Medical Physics, Quantitative Biology - Biomolecules
Abstract

Purpose: Auger emitters exhibit interesting features due to their emission of a cascade of short-range Auger electrons. Maximum DNA breakage efficacy is achieved when decays occur near DNA. Studies of double-strand breaks (DSBs) yields in plasmids revealed cutoff distances from DNA axis of 10.5-12 {\AA}, beyond which the mechanism of DSBs moves from direct to indirect effects, and the yield decreases rapidly. Some authors suggested that the average energy deposited in a DNA cylinder could explain such cutoffs. We aimed to study this hypothesis in further detail.Materials and methods: Using the Monte Carlo code CELLDOSE, we investigated the influence of the 125I atom position on energy deposits and absorbed doses per decay not only in a DNA cylinder, but also in individual strands, each modeled as 10 spheres encompassing the fragility sites for phosphodiester bond cleavage.Results: The dose per decay decreased much more rapidly for a sphere in the proximal strand than for the DNA cylinder. For example, when moving the 125I source from 10.5 {\AA} to 11.5 {\AA}, the average dose to the sphere dropped by 43%, compared to only 13% in the case of the cylinder.Conclusions: Explaining variations in DSBs yields with 125I position should consider the probability of inducing damage in the proximal strand (nearest to the 125I atom). The energy received by fragility sites in this strand is highly influenced by the isotropic (4$\pi$) emission of 125I low-energy Auger electrons. The positioning of Auger emitters for targeted radionuclide therapy can be envisioned accordingly.

Published
2024
Full Text
View/download PDF

2. Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial

Author

Mesguich, Charles, Hulin, Cyrille, Latrabe, Valerie, Asselineau, Julien, Bordenave, Laurence, Perez, Paul, Hindie, Elif, and Marit, Gerald

Subjects
Medicine, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

BackgroundThe International Myeloma Working Group recommends the use of 18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for treatment response evaluation, as it is superior to magnetic resonance imaging (MRI). However, at initial staging, the sensitivity of FDG-PET remains inferior to that of MRI. Therefore, there is a need for an imaging technique that could have a sensitivity equal to that of MRI at diagnosis and could serve to evaluate therapy. 18F-choline has shown increased sensitivity when compared with 18-FDG, with about 75% more lesions detected in patients with relapsed or progressive multiple myeloma (MM). ObjectiveOur primary objective is to prospectively compare the detection rate of bone lesions by 18F-choline PET/CT (FCH-PET) and FDG-PET in newly diagnosed MM. Our secondary objectives are to assess the accuracy of both PET modalities for the detection of bone lesions and the diagnosis of diffuse disease, to assess the detection rate of extramedullary lesions. MethodsWe will prospectively include 30 patients in a paired comparative accuracy study. Patients with de novo MM will undergo FCH-PET, FDG-PET, and whole-body MRI (WB-MRI) within a 3-week period. WB-MRI will be composed of conventional sequences on the spine and pelvis and of whole-body diffusion axial sequences. The following 6 skeletal areas will be defined: skull, sternum/costal grid, spine, pelvis, superior limbs, and inferior limbs. The number of focal lesions, their respective localization, and intensity of uptake will be retrieved for each skeletal area. Readings will be performed blinded from other imaging techniques. The reference standard will be WB-MRI. Focal lesions present on PET/CT but not on WB-MRI will require a decision made with a consensus of experts based on clinical and imaging data. The number of bone lesions and number of extramedullary lesions will be compared using the Wilcoxon test. The accuracy of FCH-PET and FDG-PET will be compared using the McNemar test. ResultsThe study started in September 2019, and enrollment is ongoing. As of June 2020, 8 participants have been included. Data collection is expected to be completed in June 2021, and the results are expected to be available in December 2021. ConclusionsThis study will assess if FCH-PET is superior to FDG-PET for the evaluation of MM tumor burden. This will pave the way for future prospective evaluations of the prognostic value of 18-FCH for treatment response evaluation in MM patients. Additionally, this work may provide new perspectives for better assessment of the risk of smoldering MM progressing to MM. Trial RegistrationClinicalTrials.gov NCT03891914; https://clinicaltrials.gov/ct2/show/NCT03891914 International Registered Report Identifier (IRRID)DERR1-10.2196/17850

Published
2020
Full Text
View/download PDF

7. Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome

Author

Tabarin, Antoine, Assié, Guillaume, Barat, Pascal, Bonnet, Fidéline, Bonneville, Jean François, Borson-Chazot, Françoise, Bouligand, Jérôme, Boulin, Anne, Brue, Thierry, Caron, Philippe, Castinetti, Frédéric, Chabre, Olivier, Chanson, Philippe, Corcuff, Jean Benoit, Cortet, Christine, Coutant, Régis, Dohan, Anthony, Drui, Delphine, Espiard, Stéphanie, Gaye, Delphine, Grunenwald, Solenge, Guignat, Laurence, Hindie, Elif, Illouz, Frédéric, Kamenicky, Peter, Lefebvre, Hervé, Linglart, Agnès, Martinerie, Laetitia, North, Marie Odile, Raffin-Samson, Marie Laure, Raingeard, Isabelle, Raverot, Gérald, Raverot, Véronique, Reznik, Yves, Taieb, David, Vezzosi, Delphine, Young, Jacques, and Bertherat, Jérôme

Published
2022
Full Text
View/download PDF

10. Actualisation des recommandations de bonne pratique clinique pour l’utilisation de la TEP en cancérologie

Author

Salaün, Pierre-Yves, Abgral, Ronan, Malard, Olivier, Querellou-Lefranc, Solène, Quere, Gilles, Wartski, Myriam, Coriat, Romain, Hindie, Elif, Taieb, David, Tabarin, Antoine, Girard, Antoine, Grellier, Jean-François, Brenot-Rossi, Isabelle, Groheux, David, Rousseau, Caroline, Deandreis, Désirée, Alberini, Jean-Louis, Bodet-Milin, Caroline, Itti, Emmanuel, Casasnovas, Olivier, Kraeber-Bodere, Françoise, Moreau, Philippe, Philip, Arnaud, Balleyguier, Corinne, Lucian, Alain, and Cachin, Florent

Published
2019
Full Text
View/download PDF

12. Good clinical practice recommendations for the use of PET/CT in oncology

Author

Salaün, Pierre-Yves, Abgral, Ronan, Malard, Olivier, Querellou-Lefranc, Solène, Quere, Gilles, Wartski, Myriam, Coriat, Romain, Hindie, Elif, Taieb, David, Tabarin, Antoine, Girard, Antoine, Grellier, Jean-François, Brenot-Rossi, Isabelle, Groheux, David, Rousseau, Caroline, Deandreis, Désirée, Alberini, Jean-Louis, Bodet-Milin, Caroline, Itti, Emmanuel, Casasnovas, Olivier, Kraeber-Bodere, Françoise, Moreau, Philippe, Philip, Arnaud, Balleyguier, Corinne, Luciani, Alain, and Cachin, Florent

Published
2020
Full Text
View/download PDF

13. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network

Author

Delyon, Julie, Chevret, Sylvie, Jouary, Thomas, Dalac, Sophie, Dalle, Stephane, Guillot, Bernard, Arnault, Jean-Philippe, Avril, Marie-Françoise, Bedane, Christophe, Bens, Guido, Pham-Ledard, Anne, Mansard, Sandrine, Grange, Florent, Machet, Laurent, Meyer, Nicolas, Legoupil, Delphine, Saiag, Philippe, Idir, Zakia, Renault, Victor, Deleuze, Jean-François, Hindie, Elif, Battistella, Maxime, Dumaz, Nicolas, Mourah, Samia, and Lebbe, Celeste

Published
2018
Full Text
View/download PDF

16. Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery

Author

Zerdoud, Slimane, Giraudet, Anne-Laure, Leboulleux, Sophie, Leenhardt, Laurence, Bardet, Stéphane, Clerc, Jérôme, Toubert, Marie-Elisabeth, Al Ghuzlan, Abir, Lamy, Pierre-Jean, Bournaud, Claire, Keller, Isabelle, Sebag, Frédéric, Garrel, Renaud, Mirallié, Eric, Groussin, Lionel, Hindié, Elif, and Taïeb, David

Published
2017
Full Text
View/download PDF

19. Membrane and Nuclear Absorbed Doses from 177Lu and 161Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study

Author

Larouze, Alexandre, Alcocer Avila, Mario Enrique, Morgat, Clement, Champion, Christophe, Hindie, Elif, Centre d'Etudes Lasers Intenses et Applications (CELIA), Université de Bordeaux (UB)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Institut de Neurosciences cognitives et intégratives d'Aquitaine (INCIA), and Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1 (UB)-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS)

Subjects
Terbium-161, 161Tb, Absorbed dose, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Targeted radionuclide therapy, 177Lu
Abstract

Early use of targeted radionuclide therapy to eradicate tumor cell clusters and micrometastases might offer cure. However, there is a need to select appropriate radionuclides and assess the potential impact of heterogeneous targeting. The Monte Carlo code CELLDOSE was used to assess membrane and nuclear absorbed doses from Lu and Tb (β-emitter with additional conversion and Auger electrons) in a cluster of 19 cells (14-μm diameter, 10-μm nucleus). The radionuclide distributions considered were cell surface, intracytoplasmic, or intranuclear, with 1,436 MeV released per labeled cell. To model heterogeneous targeting, 4 of the 19 cells were unlabeled, their position being stochastically determined. We simulated situations of single targeting, as well as dual targeting, with the 2 radiopharmaceuticals aiming at different targets. Tb delivered 2- to 6-fold higher absorbed doses to cell membranes and 2- to 3-fold higher nuclear doses than Lu. When all 19 cells were targeted, membrane and nuclear absorbed doses were dependent mainly on radionuclide location. With cell surface location, membrane absorbed doses were substantially higher than nuclear absorbed doses, both with Lu (38-41 vs. 4.7-7.2 Gy) and with Tb (237-244 vs. 9.8-15.1 Gy). However, when 4 cells were not targeted by the cell surface radiopharmaceutical, the membranes of these cells received on average only 9.6% of the Lu absorbed dose and 2.9% of the Tb dose, compared with a cluster with uniform cell targeting, whereas the impact on nuclear absorbed doses was moderate. With an intranuclear radionuclide location, the nuclei of unlabeled cells received only 17% of the Lu absorbed dose and 10.8% of the Tb dose, compared with situations with uniform targeting. With an intracytoplasmic location, nuclear and membrane absorbed doses to unlabeled cells were one half to one quarter those obtained with uniform targeting, both for Lu and for Tb. Dual targeting was beneficial in minimizing absorbed dose heterogeneities. To eradicate tumor cell clusters, Tb may be a better candidate than Lu. Heterogeneous cell targeting can lead to substantial heterogeneities in absorbed doses. Dual targeting was helpful in reducing dose heterogeneity and should be explored in preclinical and clinical studies.

Published
2023
Full Text
View/download PDF

20. Efficacy of Selective Internal Radiation Therapy for Hepatocellular Carcinoma Post-Incomplete Response to Chemoembolization.

Author

Binzaqr, Salma, Debordeaux, Frederic, Blanc, Jean-Frédéric, Papadopoulos, Panteleimon, Hindie, Elif, Lapouyade, Bruno, and Pinaquy, Jean-Baptiste

Subjects
RADIOTHERAPY, HEPATOCELLULAR carcinoma, CHEMOEMBOLIZATION, MEDIAN (Mathematics), TREATMENT effectiveness, DISEASE progression
Abstract

Hepatocellular carcinoma (HCC) is one of the most common neoplasms worldwide and the third most common cause of cancer-related death. Several liver-targeted intra-arterial therapies are available for unresectable HCC, including selective internal radiation therapy (SIRT) and trans-arterial chemoembolization (TACE). Those two are the most used treatment modalities in localized non-operable HCC. TACE is the treatment option for patients with stage B, according to the BCLC staging system. In contrast, SIRT does not have an official role in the treatment algorithm, but recent studies showed promising outcomes in patients treated with SIRT. Although TACE is globally a safe procedure, it might provoke several vascular complications such as spasms, inflammatory constriction, and, in severe cases, occlusion, dissection, or collateralization. Hence, it is acclaimed that those complications could restrain the targeted response of the radio-embolization when we use it as second-line therapy post TACE. In this study, we will assess the efficacity of SIRT using Yttrium 90 Microspheres post incomplete or failure response to TACE. In our retrospective study, we had 23 patients who met the inclusion criteria. Furthermore, those patients have been followed radiologically and biologically. Then, we evaluated the therapeutic effect according to the mRECIST criteria, in addition to the personalized dose analysis. We found 8 patients were treated with TheraSphere®, with a median tumor absorbed dose of 445 Gy, while 15 received SIR-Spheres® treatment with a mean tumor dose of 268 Gy. After radiological analysis, 56.5% of the patients had a complete response, and 17.3% showed partial response, whereas 13% had stable disease and 13% had progressive disease. For patients treated with SIRT after an incomplete response or failure to TACE, we found an objective response rate of 73.8%. Despite the known vascular complications of TACE, SIRT can give a favorable response. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. An essential practice summary of the new EANM guidelines for parathyroid imaging

Author

Petranović Ovčariček, Petra, Giovanella, Luca, Hindie, Elif, Huellner, Martin W., Talbot, Jean Noël, Verburg, Frederik A., Petranović Ovčariček, Petra, Giovanella, Luca, Hindie, Elif, Huellner, Martin W., Talbot, Jean Noël, and Verburg, Frederik A.

Abstract

Parathyroid imaging is essential for the detection and localization of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism (pHPT). Surgical treatment of pHPT mainly consists of minimally invasive parathyroidectomy (MIP), as a single adenoma represents the most common cause of this endocrine disorder. Successful surgery requires an experienced surgeon and relies on the correct preoperative detection and localization of hyperfunctioning parathyroid glands. Failure to preoperatively identify the culprit parathyroid gland by imaging may entail a more invasive surgical approach, including bilateral open neck exploration, with higher morbidity compared to minimally invasive parathyroidectomy. Parathyroid imaging may be also useful before surgery in case of secondary hyperparathyroidism (sHPT) or hereditary disorders (MEN 1, 2, 4) as it enables correct localization of typically located parathyroid glands, detection of ectopic as well as supernumerary glands. It is now accepted by most surgeons experienced in parathyroid surgery that preoperative imaging plays a key role in their patients' management. Recently, the European Association of Nuclear Medicine (EANM) issued an updated version of its Guidelines on parathyroid imaging. Its aim is to precise the role and the advantages and drawbacks of the various imaging modalities proposed or well established in the preoperative imaging strategy. It also aims to favor high performance in indicating, performing, and interpreting those examinations. The objective of the present article is to offer a summary of those recent EANM Guidelines and their originality among other Guidelines in this domain issued by societies of nuclear medicine physicians or other disciplines.

Published
2022

32. Chapter 0: Introduction to the Consensus on Primary Hyperparathyroidism from the French Society of Endocrinology, French Association of Endocrine Surgery and French Society of Nuclear Medicine

Author

Kamenicky, Peter, Mirallie, Eric, Hindie, Elif, Vantyghem, Marie-Christine, and Brunaud, Laurent

Abstract

This consensus on primary hyperparathyroidism, drawn up under the aegises of the French Society of Endocrinology (SFE), French Association of Endocrine Surgery (AFCE) and French Society of Nuclear Medicine (SFMN), provides an update on positive, etiological and differential diagnosis and treatment in primary hyperparathyroidism. These recommendations take account of recent increase in the prevalence of primary hyperparathyroidism, due to 1. more systematic routine measurement of blood calcium and improved quality of parathyroid hormone assays, 2. developments in genetics, 3. the steady increase in life expectancy, affecting the long-term consequences of asymptomatic hyperparathyroidism, 4. advances in parathyroid imaging, 5. targeted surgical management, 6. therapeutic alternatives when surgery is contraindicated, and 7. better understanding of pathophysiological mechanisms and hence of differential diagnoses, and in particular secondary and tertiary hyperparathyroidism. The consensus is published in French on the Société Française d'Endocrinologiewebsite (https://www.sfendocrino.org), and in English in the Annales d'Endocrinologie/Annals of Endocrinology and the Journal of Visceral Surgery. A summary for general practitioners will be made available on the French Health Authority (HAS) website (https://www.has-sante.fr).

Published
2025
Full Text
View/download PDF

33. A Clinical Challenge : Endocrine and Imaging Investigations of Adrenal Masses

Author

Sundin, Anders, Hindie, Elif, Avram, Anca M., Tabarin, Antoine, Pacak, Karel, Taieb, David, Sundin, Anders, Hindie, Elif, Avram, Anca M., Tabarin, Antoine, Pacak, Karel, and Taieb, David

Abstract

Incidentalomas are reported in 3%-4% of patients who undergo abdominal anatomic imaging, making adrenal mass evaluation a common occurrence. An adrenal mass can be caused by a variety of pathologies, such as benign cortical and medullary tumors, malignant tumors (primary or secondary), cysts, hyperplasia, hemorrhage, or more rarely infection/inflammation processes. Functioning tumors usually have increased hormonal production but they are less common. Regardless of their functional status, some tumors have the potential to behave aggressively. Anatomic and functional imaging together with biologic evaluation dplay a vital role in adrenal pathology subtyping. Most patients are initially evaluated by CT or MRI, which allows for tumor characterization (to a certain extent) and can rule out malignant behavior based on the absence of tumor growth during longitudinal follow-up. In the remaining patients for whom CT or MRI fail to characterize the pathogenesis of adrenal tumors, the use of specialized molecular imaging techniques should be performed after hormonal screening. This review emphasizes well-established and emerging nuclear medicine imaging modalities and describes their use across various clinical scenarios.

Published
2021
Full Text
View/download PDF

37. Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism

Author

Hindie, Elif, Urena, Pablo, Jeanguillaume, Christian, Melliere, Didier, Berthelot, Jean-Michel, Menoyo-Calonge, Victorio, Chiappini-Briffa, Dominique, Janin, Anne, and Galle, Pierre

Subjects
Hyperparathyroidism -- Diagnosis, Hyperparathyroidism -- Care and treatment, Radioisotope scanning -- Usage, Parathyroid glands -- Surgery, Parathyroid glands -- Health aspects
Published
1999

39. Consensus sur l’hyperparathyroidie primaire

Author

Vantyghem, Marie-Christine, Mirallie, Eric, Hindie, Elif, Kamenicky, Peter, and Brunaud, Laurent

Abstract

Le consensus dévolu à l’hyperparathyroïdie primaire (HPT 1), réalisé sous l’égide de la Société française d’endocrinologie, de l’Association française de chirurgie endocrinienne et de la Société française de médecine nucléaire propose une mise à jour des connaissances quant au diagnostic positif, étiologique, différentiel et au traitement de l’HPT 1. Ces propositions résumées sous la forme de recommandations tiennent compte des avancées récentes concernant sa prévalence, accrue en raison du dosage plus systématique de la calcémie en routine et de l’amélioration de la qualité des dosages de parathormone, des avancées dans l’imagerie parathyroïdienne, du développement de la génétique, de l’allongement constant de l’espérance de vie, qui influence les conséquences à long terme d’une HPT 1 dite asymptomatique, d’une prise en charge chirurgicale aujourd’hui ciblée, de la possibilité d’alternatives thérapeutiques en cas de contre-indication chirurgicale, et d’une meilleure connaissance des mécanismes physiopathologiques et donc des diagnostics différentiels notamment les hyperparathyroïdies secondaires et tertiaires. Ce consensus est publié en français sur le site de la Société française d’endocrinologie sous la forme de 16 chapitres : Introduction, Épidémiologie, Diagnostic positif, Retentissement, Diagnostic différentiel, Génétique, Formes syndromiques, Formes pédiatriques-grossesse-lactation-sujet âgé, Formes agressives, Indications thérapeutiques, Localisation, Modalités de traitement, Préparation à l’intervention-hypercalcémies aiguës, Anatomopathologie, Suivi, Guérison-récidive-persistance-parathyromatose. Il sera publié en anglais dans les Annales d’Endocrinologieet le Journal of Visceral Surgery. Un résumé destiné aux spécialistes de médecine générale sera mis à disposition sur le site de l’HAS.

Published
2024
Full Text
View/download PDF

43. Thyroid cancer recurrence in the HiLo trial

Author

HINDIE, Elif, Taieb, David, Avram, Anca, Hindié, E, Giovanella, Luca, Taïeb, D, Avram, AM., Service de médecine nucléaire, CHU Bordeaux [Bordeaux], Service de médecine nucléaire [Marseille], and Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)

Subjects
Oncology, medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, MEDLINE, Thyrotropin, 030204 cardiovascular system & hematology, medicine.disease, Iodine Radioisotopes, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Internal Medicine, Medicine, Humans, 030212 general & internal medicine, Thyroid Neoplasms, business, Thyroid cancer, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2019
Full Text
View/download PDF

45. Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial (Preprint)

Author

Mesguich, Charles, primary, Hulin, Cyrille, additional, Latrabe, Valerie, additional, Asselineau, Julien, additional, Bordenave, Laurence, additional, Perez, Paul, additional, Hindie, Elif, additional, and Marit, Gerald, additional

Published
2020
Full Text
View/download PDF

46. Good clinical practice recommendations for the use of PET/CT in oncology

Author

Salaün, Pierre-Yves, primary, Abgral, Ronan, additional, Malard, Olivier, additional, Querellou-Lefranc, Solène, additional, Quere, Gilles, additional, Wartski, Myriam, additional, Coriat, Romain, additional, Hindie, Elif, additional, Taieb, David, additional, Tabarin, Antoine, additional, Girard, Antoine, additional, Grellier, Jean-François, additional, Brenot-Rossi, Isabelle, additional, Groheux, David, additional, Rousseau, Caroline, additional, Deandreis, Désirée, additional, Alberini, Jean-Louis, additional, Bodet-Milin, Caroline, additional, Itti, Emmanuel, additional, Casasnovas, Olivier, additional, Kraeber-Bodere, Françoise, additional, Moreau, Philippe, additional, Philip, Arnaud, additional, Balleyguier, Corinne, additional, Luciani, Alain, additional, and Cachin, Florent, additional

Published
2019
Full Text
View/download PDF

47. Unmet therapeutic, educational and scientific needs in parathyroid disorders: Consensus Statement from the first European Society of Endocrinology Workshop (PARAT)

Author

Bollerslev, Jens, primary, Schalin-Jäntti, Camilla, additional, Rejnmark, Lars, additional, Siggelkow, Heide, additional, Morreau, Hans, additional, Thakker, Rajesh, additional, Sitges-Serra, Antonio, additional, Cetani, Filomena, additional, Marcocci, Claudio, additional, _, _, additional, Guistina, Andrea, additional, Van Hul, Wim, additional, Amrein, Karin, additional, Sikjaer, Tanja, additional, Hindie, Elif, additional, Vamvakidis, Kyriakos, additional, Corbetta, Sabrina, additional, Balaia, Zhanna, additional, Astor, Marianne, additional, Makay, Ozer, additional, Newey, Paul, additional, Hannan, Fadil, additional, Rolighed, Lars, additional, Appelman-Dijkstra, Natasha, additional, Wicke, Corrina, additional, Pilz, Stefan, additional, Saponaro, Federica, additional, and Vestergard, Peter, additional

Published
2019
Full Text
View/download PDF

48. Les auteurs

Author

Blondiaux, Éléonore, Durand, Emmanuel, Montaudon, Michel, Abgral, Ronan, Arrivé, Lionel, Bouallègue<ce:sup loc='post">†</ce:sup>, Fayçal Ben, Beregi, Jean-Paul, Besson, Florent, Bierry, Guillaume, Blondet, Cyrille, Blum, Alain, Bonardel, Gérald, Brunotte, François, Cachin, Florent, Cahen-Riehm, Sophie, Chabrot, Pascal, Chammas, Agathe, Chateil, Jean-François, Chevallier, Olivier, Cochet, Alexandre, Deshayes, Emmanuel, Devaux, Jean-Yves, Devred, Philippe, Ferretti, Gilbert, Fournier, Laure, Galanaud, Damien, Teixeira, Pedro Augusto Gondim, Grimon, Gilles, Hazebroucq, Vincent, Huglo, Damien, Humbert, Olivier, Keller-Petrot, Isabelle, Kharroubi, Dris, Kremer, Stéphane, de Labriolle-Vaylet, Claire, Lalande, Alain, Lebon, Vincent, Le Jeune, Florence, Le Roux, Pierre-Yves, Loffroy, Romaric, Longère, Benjamin, Lucidarme, Olivier, Lussey-Lepoutre, Charlotte, Mandry, Damien, Mariano-Goulart, Denis, Mokrane, Fatima-Zohra, Molière, Sébastien, Ohana, Mickaël, Patat, Frédéric, Pontana, François, Redheuil, Alban, Renard-Penna, Raphaële, Ronot, Maxime, Rust, Edmond, Taïeb, David, Thomassin-Naggara, Isabelle, Tourdias, Thomas, Walker, Paul Michael, Boyer, Louis, Chagnon-Lhespitaou<ce:sup loc='post">†</ce:sup>, Sophie, Chaumet-Riffaud, Philippe, Cotten, Anne, Couturier, Olivier, Croisé-Laurent, Valérie, Dacher, Jean-Nicolas, Darcourt, Jacques, le Pointe, Hubert Ducou, Ernst, Olivier, Girma, Astrid, Guiu, Boris, Hauger, Olivier, Hélénon, Olivier, Hindie, Elif, Itti, Emmanuel, Kastler, Bruno, Luciani, Alain, Marchandise, Xavier, Marie, Pierre-Yves, Marzolf, Guillaume, de Champfleur, Nicolas Menjot, Moulin, Guy, Mundler, Olivier, Olivier, Pierre, Oppenheim, Catherine, Otal, Philippe, Petit, Philippe, Pottecher, Pierre, Prigent, Alain, Rousseau, Caroline, Schneider, Fabien, Taourel, Patrice, Tasu, Jean-Pierre, and Vera, Pierre

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results